[HTML][HTML] Treatment of Fabry's disease with the pharmacologic chaperone migalastat

…, F Ezgu, H Amartino, D Bratkovic… - New england journal …, 2016 - Mass Medical Soc
Background Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency,
leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic …

[HTML][HTML] Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy

…, P Gissen, H Amartino, D Bratkovic… - … England Journal of …, 2017 - Mass Medical Soc
Background In X-linked adrenoleukodystrophy, mutations in ABCD1 lead to loss of function
of the ALD protein. Cerebral adrenoleukodystrophy is characterized by demyelination and …

Phenotype and genotype in 101 males with X-linked creatine transporter deficiency

…, I Anselm, H Azzouz, D Bratkovic… - Journal of medical …, 2013 - jmg.bmj.com
Background Creatine transporter deficiency is a monogenic cause of X-linked intellectual
disability. Since its first description in 2001 several case reports have been published but an …

Phenotypic variation of TTC19‐deficient mitochondrial complex III deficiency: A case report and literature review

…, N Manton, D Clark, D Bratkovic… - American Journal of …, 2015 - Wiley Online Library
Isolated mitochondrial respiratory chain complex III deficiency has been described in a
heterogeneous group of clinical presentations in children and adults. It has been associated …

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international …

…, M Goldman, AT Van der Ploeg, D Bratkovic… - The Lancet …, 2021 - thelancet.com
Background Pompe disease is a rare disorder characterised by progressive loss of muscle
and respiratory function due to acid α-glucosidase deficiency. Enzyme replacement therapy …

[HTML][HTML] Efficacy and safety of empagliflozin in glycogen storage disease type Ib: data from an international questionnaire

…, J Bidiuk, A Bordugo, M Boyer, D Bratkovic… - Genetics in …, 2022 - Elsevier
Purpose This paper aims to report collective information on safety and efficacy of
empagliflozin drug repurposing in individuals with glycogen storage disease type Ib (GSD …

Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C

…, A Bley, E Boltshauser, D Bratkovic… - The Journal of …, 2021 - academic.oup.com
Context 4H or POLR3-related leukodystrophy is an autosomal recessive disorder typically
characterized by hypomyelination, hypodontia, and hypogonadotropic hypogonadism …

[HTML][HTML] Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: results from a phase 2/3 randomized study

…, N Guffon, M Inbar-Feigenberg, D Bratkovic… - Molecular genetics and …, 2022 - Elsevier
Two-thirds of patients with mucopolysaccharidosis II (MPS II; Hunter syndrome) have
cognitive impairment. This phase 2/3, randomized, controlled, open-label, multicenter study …

[HTML][HTML] Pathogenic variants in glutamyl-tRNAGln amidotransferase subunits cause a lethal mitochondrial cardiomyopathy disorder

…, A Kurolap, S Palacios-Zambrano, D Bratkovic… - Nature …, 2018 - nature.com
Mitochondrial protein synthesis requires charging mt-tRNAs with their cognate amino acids
by mitochondrial aminoacyl-tRNA synthetases, with the exception of glutaminyl mt-tRNA (mt …

Mutations in ELAC2 associated with hypertrophic cardiomyopathy impair mitochondrial tRNA 3′‐end processing

…, CL Alston, E Bertini, PE Bonnen, D Bratkovic… - Human …, 2019 - Wiley Online Library
Mutations in either the mitochondrial or nuclear genomes are associated with a diverse
group of human disorders characterized by impaired mitochondrial respiration. Within this …